Dermapharm Holding SE (DMP) — Cash Flow-to-Debt Ratio
Dermapharm Holding SE (DMP) has a Cash Flow-to-Debt Ratio of 0.03x as of March 2026, meaning its operating cash flow of €39.49 Million could theoretically repay 0% of its total liabilities (€1.54 Billion) in one year. See Dermapharm Holding SE leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Dermapharm Holding SE Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Dermapharm Holding SE across 12 annual periods. For the full cash flow conversion analysis, see Dermapharm Holding SE operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Dermapharm Holding SE (2014–2025)
Year-by-year debt coverage analysis for Dermapharm Holding SE. Check Dermapharm Holding SE cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | €181.51 Million | €1.50 Billion | ▼ -11.7% |
| 2024 | 0.14x | €201.38 Million | €1.47 Billion | ▲ +0.8% |
| 2023 | 0.14x | €219.42 Million | €1.62 Billion | ▼ -58.6% |
| 2022 | 0.33x | €288.53 Million | €880.34 Million | ▲ +18.8% |
| 2021 | 0.28x | €250.37 Million | €907.13 Million | ▲ +89.4% |
| 2020 | 0.15x | €131.10 Million | €899.81 Million | ▲ +10.1% |
| 2019 | 0.13x | €100.61 Million | €760.38 Million | ▼ -62.7% |
| 2018 | 0.35x | €159.13 Million | €448.50 Million | ▲ +39.7% |
| 2017 | 0.25x | €86.74 Million | €341.62 Million | ▼ -17.0% |
| 2016 | 0.31x | €76.78 Million | €250.89 Million | ▲ +91.2% |
| 2015 | 0.16x | €40.38 Million | €252.22 Million | ▼ -12.5% |
| 2014 | 0.18x | €54.26 Million | €296.59 Million | — |